Chinese Guideline on allergen immunotherapy for allergic rhinitis
Chinese Guideline on allergen immunotherapy for allergic rhinitis
复制标题
中国变应性鼻炎变应原免疫治疗指南
DOI：
10.21037/jtd.2017.10.112
复制
发表时间：
2017-11-01
影响因子：
2.5
通讯作者：
Zhang, Luo
中科院分区：
文献类型：
--
作者：
Bao, Yixiao;Chen, Jianjun;Zhang, Luo
本文件基于中国变态反应学会（CSA）和中国过敏性鼻炎协作组（C2 AR 2G）专家组达成的共识。过敏原免疫疗法（AIT）在全球越来越多地被用作过敏性鼻炎（AR）的治疗方法，因为它已被证明在改善鼻和眼部症状，减少药物需求和改善生活质量方面具有长期效果。AIT是目前唯一的治疗性干预措施，可以潜在地改变患有AR的个体的免疫系统，并防止新的致敏性的发展和疾病从AR进展为哮喘。尽管AIT的使用在中国越来越被接受，但迄今为止，中国尚无可供国际社会使用的AR免疫治疗指南。因此，本文件已编制完成，涵盖了在中国开展的AIT的主要方面;包括AIT患者的选择、中国市场上可用的过敏原提取物、不同AIT途径中使用的过敏原时间表和剂量、效果和安全性评估、患者给药和随访以及不良反应管理。因此，中国AR免疫治疗指南将作为中国参与AR AIT的医生、医疗保健专业人员和组织的参考点。此外，本指南还将为国际社会提供有关中国AIT治疗策略的信息来源。
The present document is based on a consensus reached by a panel of experts from Chinese Society of Allergy (CSA) and Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G). Allergen immunotherapy (AIT), has increasingly been used as a treatment for allergic rhinitis (AR) globally, as it has been shown to provide a long-term effect in improving nasal and ocular symptoms, reducing medication need, and improving quality of life. AIT is currently the only curative intervention that can potentially modify the immune system in individuals suffering from AR and prevent the development of new sensitization and the progression of disease from AR to asthma. Although the use of AIT is becoming more acceptable in China, to date no AR immunotherapy guideline from China is available for use by the international community. This document has thus been produced and covers the main aspects of AIT undertaken in China; including selection of patients for AIT, the allergen extracts available on the Chinese market, schedules and doses of allergen employed in different routes of AIT, assessment of effect and safety, patients' administration and follow-up, and management of adverse reactions. The Chinese guideline for AR immunotherapy will thus serve as a reference point by doctors, healthcare professionals and organizations involved in the AIT of AR in China. Moreover, this guideline will serve as a source of information for the international community on AIT treatment strategies employed in China.